Agios Pharmaceuticals, Inc.

AGIO

NASDAQ

Healthcare

Biotechnology

Cambridge, MA, US486 employeesagios.com

$35.17

+0.98(2.87%)

Mkt Cap $2.1B

$22.34

$45.49

52-Week Range

At a Glance

AI-generated

Agios Pharmaceuticals, Inc.

Revenue breakdown: Product (100%).

8-K

Agios Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting PYRUKYND worldwide net revenues of $20.0 million in Q4 and $54.0 million for the year, AQVESME FDA approval for thalassemia with U.S. availability, and $1.2 billion in cash as of December 31, 2025.

$2.1B

Market Cap

$54M

Revenue

-$414M

Net Income

Employees486

Fundamentals

How The Business Makes Money

Revenue by Segment

Product100%($235M)

Revenue by Geography

US95.8%($112M)

Non Us4.2%($5M)

Activity

What Changed Recently

Financial Results

Feb 11, 2026

Results of Operations and Financial Condition. On February 12, 2026, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter a

Regulation FD

Jan 11, 2026

(including Exhibit 99.1 and Exhibit 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan

Peer Companies

Company	Price	Change	Market Cap	P/E
IBRXImmunityBio, Inc.	$7.30	+2.31%	$7.5B	-26.5
COGTCogent Biosciences, Inc.	$35.31	+0.21%	$5.7B	-7.3
LQDALiquidia Corporation	$37.63	+0.43%	$3.3B	-44.9
DNLIDenali Therapeutics Inc.	$20.61	+4.73%	$3.3B	-7.2
BEAMBeam Therapeutics Inc.	$24.65	+1.78%	$2.5B	-32.4
SRPTSarepta Therapeutics, Inc...	$23.20	+4.84%	$2.4B	-2.6
RCUSArcus Biosciences, Inc.	$22.95	+5.06%	$2.3B	-6.5
ETNBETNB	$14.84	+0.00%	$2.2B	—

Analyst View

Company Profile

CIK0001439222

ISINUS00847X1046

CUSIP00847X104

Phone617 649 8600

Address88 Sidney Street, Cambridge, MA, 02139-4169, US

SEC EDGAR